Xi'an Jiaotong University

About: Xi'an Jiaotong University is a education organization based out in Xi'an, China. It is known for research contribution in the topics: Heat transfer & Dielectric. The organization has 85440 authors who have published 99682 publications receiving 1579683 citations. The organization is also known as: '''Xi'an Jiaotong University''' & Xi'an Jiao Tong University.

Porous Au-Ag Nanospheres with High-Density and Highly Accessible Hotspots for SERS Analysis.

Abstract: Colloidal plasmonic metal nanoparticles have enabled surface-enhanced Raman scattering (SERS) for a variety of analytical applications While great efforts have been made to create hotspots for amplifying Raman signals, it remains a great challenge to ensure their high density and accessibility for improved sensitivity of the analysis Here we report a dealloying process for the fabrication of porous Au–Ag alloy nanoparticles containing abundant inherent hotspots, which were encased in ultrathin hollow silica shells so that the need of conventional organic capping ligands for stabilization is eliminated, producing colloidal plasmonic nanoparticles with clean surface and thus high accessibility of the hotspots As a result, these novel nanostructures show excellent SERS activity with an enhancement factor of ∼13 × 107 on a single particle basis (off-resonant condition), promising high applicability in many SERS-based analytical and biomedical applications

Global Monsoon Dynamics and Climate Change

Abstract: This article provides a comprehensive review of the global monsoon that encompasses findings from studies of both modern monsoons and paleomonsoons. We introduce a definition for the global monsoon that incorporates its three-dimensional distribution and ultimate causes, emphasizing the direct drive of seasonal pressure system changes on monsoon circulation and depicting the intensity in terms of both circulation and precipitation. We explore the global monsoon climate changes across a wide range of timescales from tectonic to intraseasonal. Common features of the global monsoon are global homogeneity, regional diversity, seasonality, quasi-periodicity, irregularity, instability, and asynchroneity. We emphasize the importance of solar insolation, Earth orbital parameters, underlying surface properties, and land-air-sea interactions for global monsoon dynamics. We discuss the primary driving force of monsoon variability on each timescale and the relationships among dynamics on multiple timescales. Natural ...

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Abstract: Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relapsed/refractory (R/R) multiple myeloma (MM). This ongoing phase 1, single-arm, open-label, multicenter study enrolled patients (18 to 80 years) with R/R MM. Lymphodepletion was performed using cyclophosphamide 300 mg/m2. LCAR-B38M CAR T cells (median CAR+ T cells, 0.5 × 106 cells/kg [range, 0.07 to 2.1 × 106]) were infused in 3 separate infusions. The primary objective is to evaluate the safety of LCAR-B38M CAR T cells; the secondary objective is to evaluate the antimyeloma response of the treatment based on the general guidelines of the International Myeloma Working Group. At data cutoff, 57 patients had received LCAR-B38M CAR T cells. All patients experienced ≥ 1 adverse events (AEs). Grade ≥ 3 AEs were reported in 37/57 patients (65%); most common were leukopenia (17/57; 30%), thrombocytopenia (13/57; 23%), and aspartate aminotransferase increased (12/57; 21%). Cytokine release syndrome occurred in 51/57 patients (90%); 4/57 (7%) had grade ≥ 3 cases. One patient reported neurotoxicity of grade 1 aphasia, agitation, and seizure-like activity. The overall response rate was 88% (95% confidence interval [CI], 76 to 95); 39/57 patients (68%) achieved a complete response, 3/57 (5%) achieved a very good partial response, and 8/57 (14%) achieved a partial response. Minimal residual disease was negative for 36/57 (63%) patients. The median time to response was 1 month (range, 0.4 to 3.5). At a median follow-up of 8 months, median progression-free survival was 15 months (95% CI, 11 to not estimable). Median overall survival for all patients was not reached. LCAR-B38M CAR T cell therapy displayed a manageable safety profile and demonstrated deep and durable responses in patients with R/R MM. ClinicalTrials.gov , NCT03090659 ; Registered on March 27, 2017, retrospectively registered